Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669561 · ClinicalTrials.gov registry record · Phase 4
The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study
A Phase 4 study of Dry Eye, sponsored by Research Insight.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT04669561 is a Phase 4 study of Dry Eye that has completed, run by Research Insight. The registered enrollment target is 100 participants, roughly in line with the 93-participant average among 41 other Dry Eye trials with a reported enrollment target. The trial reports 3 study locations across 3 states.
The verdict
NCT04669561, a Phase 4 study of Dry Eye, has completed, sponsored by Research Insight.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
In patients with dry eye, defined as corneal staining and a reduced tear breakup time, lifitegrast will improve higher order aberrations, ocular scatter index, corneal staining, and TBUT as soon as 1 week after initiating treatment.
Conditions Studied
Interventions
- DRUG Lifitegrast 5% Ophthalmic Solution
Study Locations (3)
California
- Harvard Eye Associates - Laguna Hills
Florida
- Bowden Eye & Associates - Jacksonville
Ohio
- Cleveland Eye Clinic - Brecksville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2021-10-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04669561
The ClinicalTrials.gov registry entry for NCT04669561 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 93-participant average among 41 other Dry Eye trials with a reported enrollment target. The listed sponsor is Research Insight, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Lifitegrast 5% Ophthalmic Solution is the first listed.
NCT04669561 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT04669561 about?
NCT04669561 is a clinical study titled "The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study". In patients with dry eye, defined as corneal staining and a reduced tear breakup time, lifitegrast will improve higher order aberrations, ocular scatter index, corneal staining, and TBUT as soon as 1 week after initiating treatment.
What is the current status of trial NCT04669561?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2021-03-17. Estimated completion is 2021-10-08.
What conditions does trial NCT04669561 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT04669561?
The interventions under investigation include: Lifitegrast 5% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04669561?
This trial is sponsored by Research Insight, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04669561 being conducted?
This trial has 3 study locations across California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
Performance of Systane PRO Versus Refresh Optive Mega-3
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.